Your browser doesn't support javascript.
loading
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
Sammons, Sarah; Moore, Heather; Cushman, Jaycee; Hamilton, Erika.
Affiliation
  • Sammons S; Department of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
  • Moore H; Department of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
  • Cushman J; Department of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
  • Hamilton E; Department of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
Expert Rev Anticancer Ther ; 22(8): 805-814, 2022 08.
Article in En | MEDLINE | ID: mdl-35737886
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Breast Neoplasms / Aminopyridines Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Breast Neoplasms / Aminopyridines Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Country of publication: